The clinical course meant to take the bedside clinician to the beautiful world of aesthetics, covering Neuromodulators, Dermal Fillers, Deoxycholic acid, and more!
Accreditation and Designation Statements and Disclosure Report
Neurotoxin: Introduction to History, Mechanism of Action, Facial Anatomy, Injection Technique, and
Management of Adverse Effects
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the My Face Lady Aesthetic Institute. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The enduring approval period is: October 14, 2024 – October 14, 2025
Financial Disclosures.
All planners, speakers, reviewers or staff report no relationships to disclose:
“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
Accreditation and Designation Statements and Disclosure Report
Dermal Filler: Introduction to Dermal Filler, Mechanism of Action, Facial Anatomy and the Aging Process,
Injection Technique, and Management of Adverse Effects
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the My Face Lady Aesthetic Institute. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The enduring approval period is: October 14, 2024 – October 14, 2025
Financial Disclosures.
All planners, speakers, reviewers or staff report no relationships to disclose:
“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
